Looking at the outbreak of SARS-CoV-2 and the global state of emergency imposed due to its pandemic spread, the necessity for antiviral drugs to be immediately available is a priority for the scientific community. Considering that research and implementation of new antiviral therapies or vaccines usually take a long time, the World Health Organization (WHO) has proposed to use in commerce drugs: in fact, repurposing drugs which are already accessible in large quantities is easier to fight against the virus, at least during the first emergency phase. In this article, we discuss various mathematical models which simulate the action of antiviral drug therapies, such as neuraminidase inhibitors (NIs), for the treatment of H1N1 Influenza A virus, by using data collected through in vitro and in vivo experiments. This constitutes a paradigmatic case of study for paving the way to a systematic investigation of the effects of chloroquine and hydroxychloroquine as therapeutics in the treatment of SARS-CoV-2.